Transaction · 0002081460-26-000009

Cho Esther

Cho Esther, CLO, reported an open-market or private sale at Keros Therapeutics, Inc. involving 4485.000000 shares for an estimated $46150.65. Reported holdings after the transaction were 35770.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCLO
KROSKeros Therapeutics, Inc.
Filing timeAug 20
Trade dateAug 18, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$10.95
Pre-filing
1mo ago -2.8%1w ago -2.8%1d ago -4.3%
Returns since
7d +2.6%30d +1.1%90d +1.1%180d +1.1%1y +1.1%

KROS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
KROS since 2026-08-20Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002081460-26-000009
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 08:10 PM · 2d delay
Shares
4.48k sh
$1.02k per share
Estimated value
-$4.61M
Computed from shares × price
Holdings after
35.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold…

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provid…

  3. F3

    Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.

Original filing · 0002081460-26-000009
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

KROS